178 related articles for article (PubMed ID: 19006645)
1. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis.
Nakase I; Gallis B; Takatani-Nakase T; Oh S; Lacoste E; Singh NP; Goodlett DR; Tanaka S; Futaki S; Lai H; Sasaki T
Cancer Lett; 2009 Feb; 274(2):290-8. PubMed ID: 19006645
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide.
Oh S; Kim BJ; Singh NP; Lai H; Sasaki T
Cancer Lett; 2009 Feb; 274(1):33-9. PubMed ID: 18838215
[TBL] [Abstract][Full Text] [Related]
3. Effects of artemisinin-tagged holotransferrin on cancer cells.
Lai H; Sasaki T; Singh NP; Messay A
Life Sci; 2005 Jan; 76(11):1267-79. PubMed ID: 15642597
[TBL] [Abstract][Full Text] [Related]
4. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.
Morrissey C; Gallis B; Solazzi JW; Kim BJ; Gulati R; Vakar-Lopez F; Goodlett DR; Vessella RL; Sasaki T
Anticancer Drugs; 2010 Apr; 21(4):423-32. PubMed ID: 20130467
[TBL] [Abstract][Full Text] [Related]
5. Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines.
Gong Y; Gallis BM; Goodlett DR; Yang Y; Lu H; Lacoste E; Lai H; Sasaki T
Anticancer Res; 2013 Jan; 33(1):123-32. PubMed ID: 23267137
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells.
Leto I; Coronnello M; Righeschi C; Bergonzi MC; Mini E; Bilia AR
ChemMedChem; 2016 Aug; 11(16):1745-51. PubMed ID: 26999297
[TBL] [Abstract][Full Text] [Related]
7. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells.
Sadava D; Phillips T; Lin C; Kane SE
Cancer Lett; 2002 May; 179(2):151-6. PubMed ID: 11888669
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles.
Zhang H; Ji Y; Chen Q; Jiao X; Hou L; Zhu X; Zhang Z
J Drug Target; 2015; 23(6):552-67. PubMed ID: 25754587
[TBL] [Abstract][Full Text] [Related]
9. The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells.
Herbison CE; Thorstensen K; Chua AC; Graham RM; Leedman P; Olynyk JK; Trinder D
Am J Physiol Cell Physiol; 2009 Dec; 297(6):C1567-75. PubMed ID: 19828835
[TBL] [Abstract][Full Text] [Related]
10. DNA damage in dihydroartemisinin-resistant Molt-4 cells.
Park J; Lai HC; Sasaki T; Singh NP
Anticancer Res; 2015 Mar; 35(3):1339-43. PubMed ID: 25750283
[TBL] [Abstract][Full Text] [Related]
11. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Michaelsen FW; Saeed ME; Schwarzkopf J; Efferth T
Phytomedicine; 2015 Dec; 22(14):1223-31. PubMed ID: 26655404
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the defect in a variant of HL-60 promyelocytic leukemia cells with reduced transferrin receptor expression.
Ishiguro K; Ho PT; Sartorelli AC
Somat Cell Mol Genet; 1992 Jan; 18(1):45-63. PubMed ID: 1546369
[TBL] [Abstract][Full Text] [Related]
13. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat.
Lai H; Nakase I; Lacoste E; Singh NP; Sasaki T
Anticancer Res; 2009 Oct; 29(10):3807-10. PubMed ID: 19846912
[TBL] [Abstract][Full Text] [Related]
14. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71.
Zhao F; Wang H; Kunda P; Chen X; Liu QL; Liu T
Oncol Rep; 2013 Sep; 30(3):1473-82. PubMed ID: 23818062
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
16. Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers.
Widera A; Kim KJ; Crandall ED; Shen WC
Pharm Res; 2003 Aug; 20(8):1231-8. PubMed ID: 12948021
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron.
Efferth T; Benakis A; Romero MR; Tomicic M; Rauh R; Steinbach D; Häfer R; Stamminger T; Oesch F; Kaina B; Marschall M
Free Radic Biol Med; 2004 Oct; 37(7):998-1009. PubMed ID: 15336316
[TBL] [Abstract][Full Text] [Related]
18. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1.
Ba Q; Zhou N; Duan J; Chen T; Hao M; Yang X; Li J; Yin J; Chu R; Wang H
PLoS One; 2012; 7(8):e42703. PubMed ID: 22900042
[TBL] [Abstract][Full Text] [Related]
19. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.
Daniels TR; Delgado T; Rodriguez JA; Helguera G; Penichet ML
Clin Immunol; 2006 Nov; 121(2):144-58. PubMed ID: 16904380
[TBL] [Abstract][Full Text] [Related]
20. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation.
Nakase I; Lai H; Singh NP; Sasaki T
Int J Pharm; 2008 Apr; 354(1-2):28-33. PubMed ID: 17942255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
